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ABSTRACT
Background
Controversy exists about the most appropriate treatment for high-risk superficial (stage T1;
grade G3) bladder cancer. Immediate cystectomy offers the best chance for survival but may be
associated with an impaired quality of life compared with conservative therapy. We estimated
life expectancy (LE) and quality-adjusted life expectancy (QALE) for both of these treatments for
men and women of different ages and comorbidity levels.
Methods and Findings
We evaluated two treatment strategies for high-risk, T1G3 bladder cancer using a decision-
analytic Markov model: (1) Immediate cystectomy with neobladder creation versus (2)
conservative management with intravesical bacillus Calmette-Gue ´rin (BCG) and delayed
cystectomy in individuals with resistant or progressive disease. Probabilities and utilities were
derived from published literature where available, and otherwise from expert opinion.
Extensive sensitivity analyses were conducted to identify variables most likely to influence the
decision. Structural sensitivity analyses modifying the base case definition and the triggers for
cystectomy in the conservative therapy arm were also explored. Probabilistic sensitivity analysis
was used to assess the joint uncertainty of all variables simultaneously and the uncertainty in
the base case results. External validation of model outputs was performed by comparing
model-predicted survival rates with independent published literature. The mean LE of a 60-y-
old male was 14.3 y for immediate cystectomy and 13.6 y with conservative management. With
the addition of utilities, the immediate cystectomy strategy yielded a mean QALE of 12.32 y and
remained preferred over conservative therapy by 0.35 y. Worsening patient comorbidity
diminished the benefit of early cystectomy but altered the LE-based preferred treatment only
for patients over age 70 y and the QALE-based preferred treatment for patients over age 65 y.
Sensitivity analyses revealed that patients over the age of 70 y or those strongly averse to loss
of sexual function, gastrointestinal dysfunction, or life without a bladder have a higher QALE
with conservative therapy. The results of structural or probabilistic sensitivity analyses did not
change the preferred treatment option. Model-predicted overall and disease-specific survival
rates were similar to those reported in published studies, suggesting external validity.
Conclusions
Our model is, to our knowledge, the first of its kind in bladder cancer, and demonstrated that
younger patients with high-risk T1G3 bladder had a higher LE and QALE with immediate
cystectomy. The decision to pursue immediate cystectomy versus conservative therapy should
be based on discussions that consider patient age, comorbid status, and an individual’s
preference for particular postcystectomy health states. Patients over the age of 70 y or those
who place high value on sexual function, gastrointestinal function, or bladder preservation may
benefit from a more conservative initial therapeutic approach.
The Editors’ Summary of this article follows the references.
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In North America, more than 65,000 patients are diagnosed
with bladder cancer annually [1]. The majority of cases are
superﬁcial transitional cell carcinoma (TCC), which are
usually managed by transurethral resection (TURBT). High-
grade superﬁcial TCC that invades the lamina propria of the
bladder is staged as T1G3 and may further be divided into
high-risk (multifocal and/or associated carcinoma in situ
[CIS]) or low-risk (solitary without associated CIS) categories
[2].
Currently, two main treatment options exist for the
treatment of high-risk T1G3 bladder cancer. Immediate
radical cystectomy provides the best opportunity for cure.
Cystectomy, however, is associated with short-term morbid-
ity, including perioperative death, and may impact negatively
on quality of life (QOL), because patients often develop long-
term sexual dysfunction and/or complications relating to
urinary diversion. The second up-front option consists of
repeated instillations of intravesical immunotherapy in the
form of bacillus Calmette-Gue ´rin (BCG). Responders to BCG
retain their bladder and are thereby spared cystectomy and
its associated complications, thus maintaining their QOL.
However, BCG therapy may be associated with poorer
survival outcomes compared to cystectomy for a number of
reasons. First, a number of T1G3 tumors are understaged at
TURBT and are in fact muscle invasive (stage T2). Muscle
invasive lesions carry a higher risk of metastases and death
than T1 lesions and are thus best treated with cystectomy.
Second, tumor recurrence and/or tumor progression to
muscle invasion can occur while on BCG therapy. In fact,
the 3-y risk of recurrence and progression to muscle invasion
following BCG is 80% and 35%–48%, respectively [3]. The
high progression rates of high-risk T1G3 tumors and their
potential for progression have consequently led some
urologists to favor immediate cystectomy.
Controversy exists as to the optimal treatment of patients
with high-risk T1G3 TCC. Any gain in life expectancy (LE)
from better disease control with cystectomy must be weighed
against a potential loss in QOL. Additionally, any survival
beneﬁts associated with cystectomy may be counterbalanced
by competing risks of mortality in older patients or those
with signiﬁcant comorbid medical illnesses. One technique
for comparing treatment strategies that enables incorpora-
tion of both LE and QOL and considers variables such as age
or comorbidity is decision analysis. To date, no decision
analyses have been performed for T1G3 bladder cancer. We
sought to identify the ideal strategy for patients with high-
risk T1G3 bladder cancer using a Markov decision-analytic
model.
Methods
Overview
We constructed a Markov model (TreeAge Pro Suite 2005)
to determine whether a patient with high-risk T1G3 bladder
cancer should undergo one of two strategies: (1) immediate
nerve-sparing cystectomy with orthotopic neobladder crea-
tion; (2) conservative therapy with potential for delayed
cystectomy. Radiotherapy was not considered part of the
usual treatment algorithm for these tumors. We used 6 mo
cycle lengths in order to model BCG therapy. Outcomes
assessed were LE and quality-adjusted life expectancy
(QALE).
Base Case Definition
Our base case was a 60-y-old, otherwise well, compliant and
sexually potent man with newly diagnosed high-risk T1G3
TCC. The T1G3 diagnosis was assumed to be bladder-
conﬁned and based on a TURBT containing muscularis
propria, indicating an adequate resection [4].
Model Design
Figure 1 depicts the Markov state transition diagram for
both strategies. Patients undergoing immediate cystectomy
(Figure 1A) may die postoperatively secondary to complica-
tions from cystectomy or may die of other causes in each
cycle. Survivors entered one of eight mutually exclusive
health states that are combinations of the three major
potential long-term complications of cystectomy: sexual
dysfunction, genitourinary dysfunction, and gastrointestinal
dysfunction. The probability of short-term complications
(‘‘surgically related morbidity’’) and long-term sequelae after
cystectomy were modeled independent of pathological stage
[5]. Disease recurrence after cystectomy was deﬁned as
metastases. The probability of developing metastatic disease
was based on the patient’s cystectomy pathological stage. We
assumed that all individuals with lymph node positive disease
or metastases were eligible for adjuvant [6] or palliative [7–9]
platinum-based chemotherapy, respectively. We also assumed
that the risk of metastases was dependent on tumor stage and
nodal status but independent of the local treatment strategy.
Patients undergoing conservative therapy received an
induction course of six instillations of BCG followed by 2.5
y of maintenance BCG (Figure 1B) [10]. Patients recurring
with T1G3 disease or CIS were considered BCG failures and
were eligible for a second cycle of BCG therapy. Individuals
with two BCG failures or those who progressed to muscle
invasion underwent cystectomy. At any point during BCG
therapy or its associated surveillance phase, patients were at
risk of occult metastatic disease, recurrent disease, or death
from BCG complications or other causes. As with cystectomy,
we assumed that the risk of metastases was dependent on
tumor stage and nodal status. This assumption enabled us to
incorporate both understaged and progressive T1G3 lesions
into the model. Progressive tumors had a higher T stage and
nodal metastases risk at cystectomy compared to true T1G3
lesions. Patients requiring delayed cystectomy entered post-
operative health states identical to those undergoing imme-
diate cystectomy. Movements between health states for both
treatment strategies were dictated by published probabilities.
Data Sources
We performed a MEDLINE search (1966–2005) to identify
relevant papers from which probabilities and utilities could
be obtained. For probabilities, the following text words or
medical subject headings (MeSH) were utilized: ‘‘bladder
neoplasms’’, ‘‘T1G3’’, ‘‘cystectomy’’, ‘‘BCG’’, ‘‘Bacille Calm-
ette-Guerin’’ and ‘‘follow-up studies’’. For utilities, we cross-
referenced bladder neoplasms with the text words ‘‘utility’’ or
‘‘utilities’’ and the MeSH headings ‘‘decision’’ and ‘‘quality-
adjusted life years.’’ A manual search of the reference lists
from identiﬁed studies, meta-analyses, and review articles was
performed to ensure that important articles were not missed.
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be obtained, expert opinion was sought from uro-oncologists.
Probabilities and Utilities
Probabilities. Actuarial life-tables were used to estimate the
age-speciﬁc risk of dying from other causes independent of
health state or treatment strategy [11]. Probabilities for both
treatment strategies were obtained from both randomized
controlled trials and retrospective cohort series and are listed
in Table S1. Speciﬁcally, each study was analyzed for every
possible probability in the model, and values were extracted
and tabulated accordingly. Consequently, multiple sources
for each probability estimate were often obtained. Rates
taken from time-to-event analyses were converted to semi-
annual probabilities assuming an exponential distribution
[P(x) ¼ 1   e
 uT]. Final probabilities were calculated by
weighting each article’s probabilities by its sample size.
However, if one or more articles for a given probability was
of higher quality (e.g., a randomized controlled trial) than
other sources, its published value was chosen. Plausible ranges
for each probability were deﬁned by the extremes of
published values for the given probability in situations where
multiple studies were pooled. In this manner, plausible ranges
for each probability were conservative and included the
values from all papers which reported that probability. In
situations where only one paper served as the source of a
probability, the plausible range was deﬁned by the published
95% conﬁdence interval, where available, or 6 50% of the
chosen probability value otherwise.
Utilities and treatment complications. Published utilities
for bladder cancer patients were not available. Consequently,
we derived the utility of an uncomplicated, post-cystectomy
health state from a standard gamble involving 25 urologists
and urology trainees at our institution. Comparable health
Figure 1. State Transition Diagrams for Immediate Cystectomy (A) and Conservative Therapy with BCG (B)
Abbreviations: GI comp, gastrointestinal complications (diarrhea, abdominal pain, or metabolic complications secondary to ileal resection); GU comp,
genitourinary complications (incontinence, sepsis, ureteral stenosis, or recurrent urinary tract infections); Mets, metastases; SEX comp, sexual
complications (impotence).
doi:10.1371/journal.pmed.0040284.g001
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were used for the remaining utilities in the model. These were
obtained from the Tufts-New England Medical Center Cost-
Effectiveness Analysis registry (http://www.tufts-nemc.org/
cearegistry/data/default.asp). We felt extrapolation of utilities
was reasonable given that health state preferences are deﬁned
primarily by patient symptoms, which are often similar
regardless of disease site. Nevertheless, given the uncertainty
in our utility estimates, we also reported LE outcomes in
addition to QALE outcomes in order to assess our model’s
results in the absence of utilities.
The utility of impotence and genitourinary complications
were obtained from a recent comprehensive decision analysis
for prostate cancer [12]. The utility of long-term gastro-
intestinal complications post-cystectomy was taken from
patients who have undergone ileal reservoir creation since
these individuals, like ileal neobladder patients, experience
bowel resection, reanastomosis, and reconstruction and thus
possibly similar long-term sequelae. The short-term, post-
operative utility of undergoing cystectomy was adapted from
utilities measured for abdominal hysterectomy, colostomy
creation for nonsevere trauma and radical prostatectomy
[13–15]. The utility associated with cystectomy was not
modiﬁed based on the timing of cystectomy (immediate
versus delayed while on BCG therapy), since current evidence
does not suggest a change in patient preference for
cystectomy based on its timing.
The impact of metastases was reﬂected in terms of
downstream treatment (i.e., chemotherapy), increased risk
of disease-speciﬁc mortality, and utilities associated with
metastatic disease and its treatment. The utility of metastases,
regardless of the initial treatment strategy, was assigned based
on a patient’s responsiveness to chemotherapy (i.e., ability to
achieve a complete or partial remission). The responsive
metastases health state was assigned a utility weight of 0.62.
The unresponsive metastases health state was assigned a
utility weight of 0.30. In other words, time in either of these
health states was weighted, in a multiplicative manner, by the
health state’s respective utility. Both of these values were
extrapolated from the breast cancer literature [16,17]. We
chose to extrapolate from breast cancer because the
metastatic landing zones (i.e., bones and viscera) are common
between breast and bladder cancer and thus, both patient
groups would be expected to experience similar symptoma-
tology.
We derived utilities for induction BCG, maintenance BCG,
and surveillance cystoscopy based on published utilities
associated with outpatient, moderately invasive procedures
such as cardiac catheterization [18]. We did not model the
morbidity of living with undiagnosed locally recurrent
bladder cancer because such lesions are usually asympto-
matic. The utility of diagnosis of a recurrent lesion on BCG
therapy was incorporated in the utility for a cystoscopy
(0.997) and the utility of treatment of recurrent lesions was
incorporated by assigning a disutility for TURBT of  0.06.
Recurrences that required subsequent BCG therapy were
subject to the utilities of the BCG health states as listed in
Table S1.
We applied transitional penalties (disutilities) to account
for the short term complications and inconvenience of
procedures in both arms (i.e., cystectomy, chemotherapy,
BCG, and TURBT). Similar to utilities, disutilities subtract
from a given health state’s baseline utility value. Disutilities
for cystectomy complications were based on conditions
commonly observed postoperatively [19–22]. The disutility
of chemotherapy (i.e., the inconvenience of, and symptoma-
tology arising from, chemotherapy), adapted from cancer
patients undergoing chemotherapy for breast and small cell
lung cancer, was  0.36 [16,23]. We modeled additional
morbidity in the form of chemotherapy-speciﬁc complica-
tions such as death, febrile neutropenia, severe mucositis, etc.
using a disutility value for nonlethal chemotherapy compli-
cations of  0.54 [17]. Death in all circumstances was assigned
a utility of 0. Uncertainty around utility estimates was set to
include estimates from all studies reporting a similar utility
or, where multiple studies were unavailable, 6 50% of the
base case estimate.
Model Assumptions
First, we assumed that long-term complications following
radical cystectomy are static (time-independent) and not
correlated with one another. Second, we assumed that upper
tract and urethral recurrences are likely to develop inde-
pendent of the treatment choices offered and thus will not
bias results in either direction. Third, we assumed that only
one recurrence on conservative therapy could occur per 6 mo
cycle. This assumption allowed for two recurrences in the ﬁrst
year on BCG or, alternatively, two potential BCG failures in
the ﬁrst year of conservative therapy. Fourth, we assumed
equal progression and recurrence rates while in the main-
tenance and surveillance health states of each respective BCG
cycle and that risks of recurrence and progression were
higher in patients requiring a second cycle of BCG [24]. Fifth,
we assumed that all utility values were time- and age-
independent.
Comorbidity Adjustment
Rate ratios for comorbidity from two retrospective bladder
cancer studies, one assessing long-term, overall mortality [25]
for patients with invasive bladder cancer and the other
postoperative (short-term) mortality [26] for cystectomy
patients, modiﬁed the probability of mortality from non-
bladder cancer causes and the probability of postcystectomy
mortality in a multiplicative manner, respectively.
Validation
We assessed the ability of our model to reproduce medium-
term (5-y) and long-term (10- or 15-y) overall survival and
disease-speciﬁc survival rates in both treatment arms by
comparing model-generated survival estimates with those
published in large studies that were separate from those used
to generate model probabilities.
Sensitivity Analyses
One-way sensitivity analyses. To assess the stability of our
results, one-way sensitivity analyses were performed by
varying each probability and utility between 0 and 1 (the
broadest range possible). Thresholds were identiﬁed for
sensitive variables either within or outside their plausible
ranges. Also, by reporting both LE and QALE outcomes, we
were able to assess the model’s robustness without the
uncertainty of our utility estimates.
Structural sensitivity analyses. Although we assumed that
patients treated with initial BCG would move on to
cystectomy after suffering two BCG failures over a minimum
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failures in the ﬁrst six months of therapy (early failures) or
cystectomy following a single BCG failure are recognized
alternative strategies [2,27]. We explicitly explored these
alternative scenarios in our model using structural sensitivity
analyses. We also tested our modeling assumption limiting
the number of recurrences to two in one year by allowing a
third recurrence in the ﬁrst year of therapy and determining
the impact on model outcomes.
Finally, we assessed the impact of varying our base case
deﬁnition. Speciﬁcally, we determined outcomes for women
as the base case (instead of men) and for men with preexisting
erectile dysfunction (instead of potent men). These modiﬁ-
cations increased the generalizability of our model by
including important patient populations who were not fully
represented by our original base case deﬁnition.
Probabilistic sensitivity analyses. We performed probabil-
istic sensitivity analysis using 1,000 second-order Monte Carlo
simulations. This process allowed us to address the joint
uncertainty of all model parameters simultaneously and
provided a more accurate estimate of the average health
outcomes of each strategy. To perform this analysis, we
modeled all of our input variables as distributions. We
assumed that ‘‘transition probabilities’’ (probabilities of
moving from one health state to another) followed an
exponential distribution and calculated corresponding tran-
sition rates and standard errors for each study. These values
were used to estimate the parameters of a gamma distribution
using the method of moments [28]. We selected gamma
distributions because, like transition rates, the range of
possible values is bounded by zero and inﬁnity. Thus, in each
run of the model, we randomly sampled each transition rate
from that parameter’s gamma distribution and converted this
rate back to a transition probability. We modeled ‘‘event
probabilities’’ (probabilities of a one-time event) and utility
scores by using beta distributions (bounded by 0 and 1)
deﬁned by the estimate and standard error of each
parameter. In each run of the model, we sampled each event
probability and utility from that respective parameter’s beta
distribution.
Results
Base Case LE and QALEs
The average (mean) LE of a 60-y-old, potent man with high-
risk disease and no comorbidities undergoing immediate
cystectomy was 14.29 y. With conservative management, the
Table 1. One-Way Sensitivity Analysis Results for a 60-Year-Old Potent Male: Comorbid Status and Probabilities
Category Variable Subcategory Base
Case
Plausible
Range
Threshold
(to Favor BCG)
Comorbid status Short-term None 1.0 1.0–2.0 .2.6
a
Mild 1.37 1.0–2.7 .2.6
a
Moderate 1.73 1.0–3.5 .2.6
a
Long-term None 1.0 1.0–2.0 .2.3
a
Mild 1.11 1.0–2.2 .2.3
a
Moderate 1.48 1.0–3.0 .2.3
a
Probabilities Age at diagnosis (y) 60 30–90 .69
a
Postoperative mortality after cystectomy 0.04 0.007–0.064 TOPR (.0.11)
Postcystectomy complication 0.267 0.2–0.304 NT
True invasive disease for a clinically
diagnosed T1G3 cancer
0.376 0.22–0.62 TOPR (,0.16)
Positive lymph nodes with invasive disease
b 0.202 0.168–0.505 TOPR (,0.04)
Gastrointestinal complication after cystectomy 0.316 0.09–0.395 NT
Genitourinary complication after cystectomy 0.1 0.075–0.256 NT
Impotence after cystectomy 0.59 0.33–1.0 NT
Metastatic disease after cystectomy
c 0.054 0.04–0.32 TOPR (,0.018)
Mortality from chemotherapy 0.025 0.01–0.04 NT
Response to chemotherapy for metastatic cancer 0.425 0.381–0.57 NT
Developing progressive metastases given a
response to chemotherapy
0.364 0.315–0.417 NT
Chemotherapy complication 0.661 0–0.72 NT
Mortality from metastatic cancer 0.43 0.215–0.645 NT
Mortality from BCG therapy 0.003 0–0.005 NT
BCG complication 0.286 0.18–0.67 NT
Recurrence on BCG
d 0.034 0.026–0.166 TOPR (,0.023)
Progression on BCG
d 0.311 0.115–0.53 ,0.15
a
Developing high risk disease given a nonprogressive recurrence
e 0.133 0.065–0.29 NT
T1G3 tumor given nonprogressive, ‘‘low risk’’ tumor recurrence 0.558 0.23–0.88 NT
aSensitive within threshold range. For progression on BCG, a threshold value of 0.15 translates into a conditional probability of progression of 0.21 during the first induction and
maintenance cycles of BCG and a probability between 0.15 and 0.23 during a second cycle of BCG depending on whether the recurring tumor was low or high risk, respectively. Values
lower than these would favor conservative therapy.
bProbability of positive nodes given noninvasive disease modeled as a multiple of this variable.
cBaseline value for patients with locally invasive, lymph node-positive TCC.
dBaseline values for patients with low-risk disease on surveillance (time-dependent).
eBaseline value for an original low-risk tumor.
NT, no threshold; TOPR, threshold outside of plausible range
doi:10.1371/journal.pmed.0040284.t001
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preferred by 0.66 y. With the addition of utilities, the
immediate cystectomy strategy yielded an average QALE of
12.32 y and remained preferred over conservative therapy by
0.35 QALY (quality-adjusted life years).
Base Case Validation
For radical cystectomy outcomes, our model predicted 5-
and 10-y overall survival rates of 80% and 62%, respectively,
which are consistent with the respective rates of 78% and
58% reported by Stein et al. [29]. The 5-y, model-predicted,
overall survival rate in the conservative therapy arm was 81%,
which mirrors published literature [3,10,30]. The 15-y
predicted overall survival rate in the conservative therapy
arm was 41%, similar to the published long-term result of
37% for high-risk T1 and/or CIS patients [3].
For immediate cystectomy, the 5- and 10-y disease-speciﬁc
survival rates generated by the model were 91% and 82%,
respectively, which are similar to the respective 90% [31] and
83% [32] rates reported in the literature. Our model
produced 5- and 10-y disease-speciﬁc survival rates of 90%
and 79%, respectively, for conservative therapy compared to
observed rates of 87% and 75%, respectively [30,33].
One-Way Sensitivity Analyses
For the base case (60-y-old males), the preferred therapy
was sensitive to four probabilities and three utilities (Tables 1
and 2, respectively). Patient age at diagnosis and comorbidity
were the most inﬂuential probabilities (see below). Other
important variables included the conditional probability of
developing a progressive tumor given a recurrence and the
utilities for impotence, gastrointestinal complications, and
urinary diversion (i.e., the postcystectomy state).
Impact of Age and Comorbidity
Health outcomes for men at various age intervals are
displayed in Figure 2. Preferred treatment strategies were
most susceptible to change between the ages of 75 and 85 y
for mean LE outcomes, and 65 to 75 y for mean QALE
outcomes and most consistent outside of these age ranges.
After the age of 80 y, the treatment with the greatest mean LE
changed from immediate cystectomy to conservative manage-
ment. Likewise, as men approach the age of 70 y, the
treatment with the greatest mean QALE changed to
conservative therapy.
Incorporating comorbidity into the LE model did not
signiﬁcantly alter the mean results for the base case (male, age
60) or for very young or very old patients (Figure 3). Where
mean LE outcomes were considered, comorbid status was
most important for patients between the ages of 70 and 80 y.
Speciﬁcally, immediate cystectomy yielded a higher mean LE
only for 70-y-old men with no or mild comorbidity and 75-y-
old men without comorbid illness. For individuals aged 80 y, a
treatment decision could not be made based on LE for those
with no comorbidity given the near equivalent mean LE of
both treatment strategies. With respect to mean QALE
outcomes (Figure 4), comorbidity most inﬂuenced outcomes
for men between the ages of 60 and 70 y. For the base case,
cystectomy was favored in situations where comorbidity was
absent or mild. However, for a 60-y-old man with moderate
comorbidity, immediate cystectomy was associated with such
a small incremental mean QALE gain (0.04 QALY) that a
preferred treatment could not be identiﬁed with certainty.
Similar uncertainty existed for a 70-y-old man with no
comorbidity. Individuals above age 60 with moderate
comorbidity had a higher average QALE with conservative
therapy. Assessing the impact of comorbidity in the LE model
revealed similar trends (Figure 4).
Structural Sensitivity Analyses
The impact of various triggers for cystectomy during BCG
therapy was assessed via structural sensitivity analyses (Table
3). A total of three scenarios were compared: (1) The base case
in which cystectomy was triggered after two BCG failures,
deﬁned as a T1G3 recurrence after a second cycle of BCG; (2)
cystectomy after a single BCG failure, deﬁned as a T1G3
recurrence after a single cycle of BCG; or (3) cystectomy after
an early BCG failure (during the ﬁrst 6 mo of BCG therapy).
In all three scenarios, the mean LE and QALE estimates for
conservative therapy changed minimally and did not alter the
preferred treatment.
Table 2. One-Way Sensitivity Analysis Results for a 60-Year-Old Potent Male: Utilities and Disutilities
Utility or Disutility Base Case Plausible Range Threshold (to Favor BCG)
Cystectomy 0.8 0.5 to 1.0 NT
Gastrointestinal complication after cystectomy 0.97 0.69 to 1.0 ,0.76
a
Genitourinary complication after cystectomy 0.93 0.57 to 1.0 TOPR (,0.25)
Impotence after cystectomy 0.91 0.69 to 1.0 ,0.80
a
Metastases responsive to chemotherapy 0.62 0.31 to 0.93 NT
Metastases unresponsive to chemotherapy 0.3 0.13 to 0.62 NT
Surveillance cystoscopy 0.997 0.95 to 1.0 NT
Postcystectomy state 0.96 0.72 to 1.0 ,0.89
a
Cystectomy complication  0.3  0.5 to  0.02 NT
Chemotherapy  0.36  0.9 to  0.2 NT
Chemotherapy complication  0.54  0.76 to  0.32 NT
BCG therapy—induction  0.02  0.3 to 0 NT
BCG complication  0.2  0.4 to 0 NT
TURBT for low-risk Ta lesions  0.1  0.03 to  0.09 NT
aSensitive within threshold range.
NT, no threshold; TOPR, threshold outside of plausible range.
doi:10.1371/journal.pmed.0040284.t002
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model’s health outcomes. For example, female patients had
similar, albeit slightly larger, average LE and QALE outcomes
compared to males (Figure 2, lower box plot). Likewise, the
mean QALE for patients with preexisting erectile dysfunction
was 0.62 y higher with immediate cystectomy compared to
initial conservative management (12.99 y versus 12.37 y).
Allowing a third recurrence on BCG in the ﬁrst year of
therapy also did not materially inﬂuence the results, with the
net mean incremental QALE gain for immediate cystectomy
decreasing by only 0.06 y.
Probabilistic Sensitivity Analyses
Jointly varying the input parameters in a probabilistic
sensitivity analysis did not alter the treatment decision. The
mean LE for the base case via probabilistic sensitivity analysis
was 14.61 y (interquartile range [IQR] 13.81–15.63 y) for
immediate cystectomy and 13.89 y (IQR 13.03–14.92 y) for up-
front BCG. Likewise, the base case mean QALEs were 12.62 y
(IQR 11.35–14.49 y) and 12.24 y (IQR 11.03–13.69 y) for
radical and conservative management, respectively. With
respect to QALE, 74% of simulations favored an up-front
cystectomy, which can be considered moderate to good
Figure 2. Box Plots of Incremental Gain in LE and QALE with Immediate Cystectomy by Age for Male (Upper Plot) and Female Patients (Lower Plot)
The region in the shaded boxes of both plots represents the interquartile range. The solid line within boxes is the median incremental gain, whereas the
mean value is presented as an ‘‘3’’. Upper and lower whiskers indicate the 10th and 90th percentiles, respectively.
doi:10.1371/journal.pmed.0040284.g002
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T1G3 Bladder Cancer Decision Analysiseffectiveness. In other words, we are 74% conﬁdent that
cystectomy is the preferred choice for high-risk T1G3 lesions
in base case patients. Assuming a minimal clinically impor-
tant difference of 0.2 QALE (2.4 mo) for one strategy to be
truly favored, 67% of simulations still favored immediate
cystectomy, 21% favored BCG, and 12% of simulations were
indifferent (that is, neither strategy was better by at least 0.2
QALE). For 50-y-old patients, 78% of simulations favored
cystectomy, whereas 55% of simulations favored BCG for 85-
y-old patients. Similar results were found for LE simulations
(89% for immediate cystectomy for 50-y-old patients; 66%
for conservative therapy for 85-y-old patients).
Probabilistic sensitivity analysis also enabled calculation of
credible intervals for our comparisons of the two treatment
strategies. These are represented in Figures 2, 3, and 4 in the
form of box-and-whisker plots. The uncertainty implied by
the credible intervals, coupled with the fact that immediate
cystectomy is favored in the majority (74%) of simulations for
the base case, indicate a skewed distribution of incremental
gains as depicted in Figure 5. Incremental gains with
Figure 3. Box Plot of Gain in LE with Immediate Cystectomy by Age and Comorbid Status for Male Patients
The region in the shaded boxes represents the interquartile range. The solid line within boxes is the median incremental gain, whereas the mean value
is presented as an asterisk. Upper and lower whiskers indicate the 10th and 90th percentiles, respectively.
doi:10.1371/journal.pmed.0040284.g003
Figure 4. Box plot of Gain in QALE with Immediate Cystectomy by Age and Comorbid Status for Male Patients
The region in the shaded boxes represents the interquartile range. The solid line within boxes is the median incremental gain, whereas the mean value
is presented as an asterisk. Upper and lower whiskers indicate the 10th and 90th percentiles, respectively.
doi:10.1371/journal.pmed.0040284.g004
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T1G3 Bladder Cancer Decision Analysiscystectomy are skewed because simulations with a high
postoperative death rate postcystectomy result in large gains
for conservative management for a minority of patients.
Discussion
We found that for an otherwise healthy, 60-y-old sexually
potent man with high-risk T1G3 bladder cancer, the mean LE
was 7.9 mo higher if he decided to undergo immediate radical
cystectomy instead of conservative management. Consider-
ation of QOL led to a slightly smaller gain of 4.2 mo in favor
of early cystectomy but did not alter the preferred treatment
option. Comorbidity was most inﬂuential on the treatment
decision for patients between the ages of 60 and 70 y. One-
way sensitivity analyses revealed that patients over the age of
70 or those strongly averse to loss of sexual function,
gastrointestinal dysfunction, or life without a bladder had a
higher QALE with conservative therapy. Neither structural
sensitivity analyses nor probabilistic sensitivity analyses
altered the optimal base case treatment strategy.
This work represents, to our knowledge, the ﬁrst systematic
evaluation of the two main treatment strategies for high-risk
T1G3 TCC of the bladder. While the best means of comparing
two or more treatment strategies is a randomized controlled
trial, such a methodology may not be feasible for T1G3
cancer, given the difﬁculties inherent in randomizing
patients to invasive versus less invasive therapies in surgical
trials [34]. Indeed, we are not aware of any planned or
ongoing trial examining this issue. These pragmatic issues
therefore position a decision analytic model as an important
methodology to address the T1G3 TCC controversy.
We have identiﬁed several important factors that are
relevant to decision-making in the setting of high-risk T1G3
bladder cancer. Patient age and comorbid status were the
most important variables driving the decision in our model.
Our analysis also identiﬁed three key utilities that may
potentially sway the treatment decision for patients. Specif-
ically, patients who place great value on preserving sexual
function and/or those who are strongly averse to gastro-
intestinal symptomatology or to living with a urinary
diversion may fare better with conservative management.
While our model assumed a cystectomy technique incorpo-
rating nerve sparing and creation of an orthotopic ileal
neobladder, deviation from this approach (i.e., urostomy and/
or non-nerve-sparing) could diminish the utility associated
with urinary diversion and/or alter the probability of post-
operative sexual complications, and thereby alter the treat-
ment decision. Reports published to date, however, do not
support signiﬁcant QOL differences based on the type of
urinary diversion [35,36]. Nevertheless, these studies do not
measure utilities and it remains possible that small QOL
differences may generate differences in utility values that
could then impact the results of our model. However, the
extent to which alternative surgical techniques affect bladder
cancer patient utilities has not been studied and is a focus for
future research. In addition to the factors identiﬁed in this
study, patient anxiety, fear, and circumstances unique to each
case (e.g., social or ﬁnancial concerns), which are not
addressed by our model, should also be considered in the
T1G3 decision-making process.
We assumed that patients embarking on a bladder
conservation treatment strategy could undergo salvage
cystectomy after developing a T1G3 recurrence after two
cycles of BCG. Since the timing of cystectomy while on BCG
therapy is contentious, we performed structural sensitivity
analyses by modifying the triggers for cystectomy to reﬂect
the varied practice patterns of urologists (Table 3). Regardless
of the point at which cystectomy was offered to a patient on
BCG therapy, immediate cystectomy conferred a higher
incremental LE and QALE gain compared to conservative
management for our base case. Alternative base case
scenarios (e.g., preexisting sexual dysfunction, female patient,
or multiple recurrences) also did not alter the preferred
treatment, further pointing to the robustness of our results.
Our base case was diagnosed with a high-risk T1G3 lesion
after a single TURBT. Current evidence suggests that the
standard of care for T1G3 disease is shifting away from a
single TURBT to re-resection with a second TURBT prior to
embarking on a treatment decision [37,38]. A repeat TURBT
could help identify patients with invasive disease and thereby
decrease the proportion of patients who inappropriately
receive BCG. Improved patient selection with two TURBT
procedures would be reﬂected in diminished recurrence and
progression rates and thus improved outcomes while on
conservative therapy. We were able to examine the beneﬁt of
a second TURBT after a T1G3 diagnosis via a sensitivity
analysis on the probability of occult invasive disease (Table 1).
According to our model, this proportion would have to be
reduced to 16%, a potentially reasonable target after two
TURBTs, to alter the treatment decision. Further long-term
outcome data after two TURBTs are necessary to ultimately
validate this cut-point. Improvements in conservative therapy
could also alter the treatment decision by decreasing
recurrence and progression rates. Our model supported this
possibility by identifying threshold recurrence and progres-
sion values below which conservative therapy was favored.
The insights gained from our model are consistent with
international guidelines on the treatment of T1G3 TCC of
the bladder [2,27]. They also provide additional clariﬁcation
that has not previously been reported. In particular, our
study is the ﬁrst, to our knowledge, to quantify the age ranges
that may potentially be associated with suboptimal health
outcomes following immediate cystectomy for high-risk T1G3
bladder cancer. The available guidelines also list comorbid
status as an important determinant guiding treatment
decisions, but provide no details to clarify decision-making.
Our analysis reﬁnes this concept by demonstrating that
comorbidity is most likely to affect the preferred treatment
Table 3. Impact of Alternative Triggers for Radical Cystectomy
during Initial BCG Therapy
Scenario
a Mean LE (Years) Mean QALE (Years)
Two BCG failures (base case) 13.63 11.97
One BCG failure 13.82 12.09
Early BCG failure 13.70 12.02
Immediate cystectomy (reference) 14.29 12.32
See text for scenario definition details
aCystectomy indicated for progression regardless of scenario.
doi:10.1371/journal.pmed.0040284.t003
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between 60 and 70 for LE and QALE outcomes, respectively.
Validity assessment suggests that our model is accurate
since the survival rates it generated concurred with those in
the published literature. Nevertheless, important limitations
to this study exist. First, many of the studies from which
probabilities were drawn were retrospective in nature with
possible selection biases. For example, long-term cystectomy
series may have excluded patients with signiﬁcant comorbid-
ity, whereas concurrent BCG series may have included such
individuals. Along with disease-speciﬁc external validation,
which may theoretically address some of the selection biases
inherent in using overall survival as an outcome, we also
attempted to deal with this limitation by identifying the
highest-quality studies and by conducting extensive sensitiv-
ity analyses. Second, a lack of utility data for bladder cancer
patients forced us to either extrapolate utilities from similar
disease states or use clinician-derived utilities. Although we
feel these utilities are representative, and were varied widely
in sensitivity analyses to reﬂect the uncertainty inherent to
extrapolation, they may not fully characterize the preferences
of bladder cancer patients. For this reason, we also reported
life expectancy outputs from our model, which were
independent of utilities and gave similar results. Nevertheless,
elicitation of utilities from bladder cancer patients, partic-
ularly those utilities to which the model was sensitive, is an
important area of future research. Third, we deﬁned our base
case after a single TURBT. As we alluded to above, many
urologists are now offering a second TURBT soon after the
initial resection to better risk-stratify patients. Repeat
TURBT, however, is a relatively new approach in the
treatment of high-risk T1G3 tumors, and thus data on
outcomes after a second resection are only now emerging
[38–40]. Consequently, a lack of available long-term outcomes
data precluded us from using a T1G3 diagnosis based on a
second TURBT in our base case. As this information becomes
increasingly available, we will be able to incorporate it into
future iterations of our model. As a novel treatment
approach, there is also little evidence that suggests that
repeat TURBT has been routinely adopted by most urologists,
which suggests that our model in its current form is relevant
to contemporary clinical practice. Nevertheless, we were able
to model the effect of a second TURBT by varying our
probability of occult invasive disease in one-way sensitivity
analyses and have reported these analyses. Fourth, our model
only allowed for a maximum of two disease recurrences in
one year. Although rare, three recurrences may occur in a
year on conservative therapy. Since the preferred treatment
was cystectomy rather than conservative management, this
limitation is unlikely to impact materially on our results. This
notion was supported via structural sensitivity analyses in
which we explored three recurrences on BCG in the ﬁrst year
of therapy. Fifth, we did not explicitly consider noncom-
pliance or dose-reduced BCG protocols in our model, since
most studies reporting recurrence and progression rates with
BCG therapy incorporate patients with poor compliance or
dose reductions [10,41]. Nevertheless, although diminished
compliance with BCG has not been shown to affect
recurrence or progression rates [42], some clinicians may
recommend immediate cystectomy if patient compliance
with BCG is a concern.
Despite these limitations, the paucity of sensitive variables
illustrates the robustness of our results. Furthermore, a mean
difference of 7.9 mo of LE and 4.2 mo of QALE for the base
case analysis is considered moderate to substantial by medical
decision makers. While these values may seem small, LE gains
in decision models are diluted across patients and represent
average values, thus making a gain of this magnitude
considerable. The actual clinical signiﬁcance of a gain in life
expectancy from a decision model can be determined by
comparing the obtained gain with results derived from widely
accepted interventions in similar populations [43]. The LE
Figure 5. Incremental QALE Gains for the Base Case
The histogram depicts the distribution of results of 1,000 Monte Carlo simulations for 60-y-old male patients without comorbidity. Positive values
indicate a larger QALE for immediate cystectomy as compared to conservative therapy. The distribution is skewed to the left.
doi:10.1371/journal.pmed.0040284.g005
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interventions in adults with established disease. For example,
routine beta-blocker therapy in men at moderate risk of
recurrence after a myocardial infarction is an established
treatment modality and is associated with a gain in LE of
approximately 4.1 mo [44]. Likewise, myocardial revasculari-
zation with coronary artery bypass grafting for coronary
artery disease confers a 1–7, 0–8, and 4–14 mo gain in LE for
single, double, and triple vessel disease, respectively [18]. The
gains in LE from both of these generally accepted and widely
practiced interventions are in line with those generated by
our model, supporting the importance of our model’s
outcomes.
In conclusion, our model demonstrates that an otherwise
well 60-y-old patient with high-risk T1G3 TCC of the bladder
would have a higher LE and QALE with immediate
cystectomy. The decision to pursue immediate cystectomy
versus conservative therapy should be based on discussions
that consider patient age, comorbid status, and an individ-
ual’s preference for particular postcystectomy health states.
Patients who place great emphasis on preserving sexual
function or who are strongly averse to living with chronic
gastrointestinal symptoms or a neobladder may maximize
their health outcomes with a bladder-sparing regimen.
Supporting Information
Table S1. Model Semiannual Probabilities and Utilities
Semiannual probabilities and the utilities/disutilities used to populate
the decision model.
Found at doi:10.1371/journal.pmed.0040284.st001 (128 KB DOC).
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Editors’ Summary
Background. Every year, about 67,000 people in the US develop bladder
cancer. Like all cancers, bladder cancer arises when a single cell begins to
grow faster than normal, loses its characteristic shape, and moves into
surrounding tissues. Most bladder cancers develop from cells that line
the bladder (‘‘transitional’’ cells) and most are detected before they
spread out of this lining. These superficial or T1 stage cancers can be
removed by transurethral resection of bladder tumor (TURBT). The
urologist (a specialist who treats urinary tract problems) passes a small
telescope into the bladder through the urethra (the tube through which
urine leaves the body) and removes the tumor. If the tumor cells look
normal under a microscope (so-called normal histology), the cancer is
unlikely to return; if they have lost their normal appearance, the tumor is
given a ‘‘G3’’ histological grade, which indicates a high risk of recurrence.
Why Was This Study Done? The best treatment for T1G3 bladder cancer
remains controversial. Some urologists recommend immediate radical
cystectomy— surgical removal of the bladder, the urethra, and other
nearby organs. This treatment often provides a complete cure but can
cause serious short-term health problems and affects long-term quality
of life. Patients often develop sexual dysfunction or intestinal (gut)
problems and sometimes find it hard to live with a reconstructed
bladder. The other recommended treatment is immunotherapy with
bacillus Calmette-Gue ´rin (BCG, bacteria that are also used to vaccinate
against tuberculosis). Long-term survival is not always as good with this
conservative treatment but it is less likely than surgery to cause short-
term illness or to reduce quality of life. In this study, the researchers have
used decision analysis (a systematic evaluation of the important factors
affecting a decision) to determine whether immediate cystectomy or
conservative therapy is the optimal treatment for patients with T1G3
bladder cancer. Decision analysis allowed the researchers to account for
quality-of-life factors while comparing the health benefits of each
treatment for T1G3 bladder cancer.
What Did the Researchers Do and Find? Using a decision analysis
model called a Markov model, the researchers calculated the months of
life gained, and the quality of life expected to result, from each of the
two treatments. To estimate the life expectancy (LE) associated with each
treatment, the researchers incorporated the published probabilities of
various outcomes of each treatment into their model. To estimate
quality-adjusted life expectancy (QALE, the number of years of good
quality life), they incorporated ‘‘utilities,’’ measures of relative satisfac-
tion with outcomes. (A utility of 1 represents perfect health; death is
assigned a value of 0, and outcomes considered less than ideal, but
better than death, fall in between). For a sexually potent 60-year-old man
with bladder cancer but no other illnesses, the average LE predicted by
the model was nearly eight months longer with immediate cystectomy
than with conservative treatment (both LEs predicted by this model
matched those seen in clinical trials); the average QALE with cystectomy
was 4.2 months longer than with conservative treatment. Having
additional diseases decreased the benefit of immediate cystectomy but
the treatment still gave a longer LE until the patient reached 70 years
old, when conservative treatment became better. For QALE, this change
in optimal treatment appeared at age 65. Finally, conservative treatment
gave a higher QALE than immediate cystectomy for patients concerned
about preserving sexual function or averse to living with intestinal
problems or a reconstructed bladder.
What Do These Findings Mean? As with all mathematical models, these
results depend on the assumptions included in the model. In particular,
because published probability and utility values are not available for
some of the possible outcomes of the two treatments, the LE and QALE
calculations could be inaccurate. Also, assigning numerical ratings to life
experiences is generally something of a simplification, which could affect
the reliability of the QALE (but not the LE) results. Nevertheless, these
findings provide useful guidance for urologists trying to balance the
benefits of immediate cystectomy or conservative treatment against the
potential short-term and long-term effects of these treatments on
patients’ quality of life. Specifically, the results indicate that decisions on
treatment for T1G3 bladder cancer should be based on a consideration
of the patient’s age and any coexisting disease coupled with detailed
discussions with the patient about their attitudes regarding the possible
health-related effects of cystectomy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040284.
  MedlinePlus encyclopedia page on bladder cancer (in English and
Spanish)
  Information for patients and professionals from the US National
Cancer Institute on bladder cancer (in English and Spanish)
  Information for patients on bladder cancer from the UK charity
Cancerbackup
  Online course on Decision Analysis in Health Care from George Mason
University
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